Market
AMD's AI chip market share in drug discovery by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports from industry analysts or financial institutions
Story
AMD Invests $20 Million in Absci via PIPE to Enhance AI Drug Discovery with AMD GPUs
Jan 8, 2025, 01:19 PM
Advanced Micro Devices Inc. (AMD) has announced a strategic investment of $20 million in Absci Corporation (ABSI), a company focused on AI-driven drug discovery. The investment, structured as a private investment in public equity (PIPE), aims to enhance AMD's presence in the healthcare sector by leveraging its artificial intelligence chips. This collaboration will see Absci deploying AMD's high-performance compute and software solutions to advance the development of next-generation antibody therapeutics. The partnership is part of AMD's broader strategy to expand into life sciences and other industries, positioning its graphics processing units (GPUs) for specialized applications. Absci, based in Washington state, currently utilizes over 470 AI chips, predominantly from Nvidia, but plans to increase its use of AMD's GPUs following this investment.
View original story
Similar markets
20% to 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
More than 30% • 25%
Increased • 25%
No change • 25%
Decreased • 25%
Other • 25%
Nvidia partners or merges with another major tech company • 25%
Nvidia faces strong competition but stays competitive • 25%
Nvidia remains the leader • 25%
Nvidia loses significant market share • 25%
Leader (>40%) • 25%
Minor Player (5-20%) • 25%
Major Player (20-40%) • 25%
Niche Player (<5%) • 25%
Not adopted • 25%
Minimal adoption • 25%
Partially adopted in some pipelines • 25%
Fully adopted across all pipelines • 25%
Yes • 50%
No • 50%
Above 30% • 25%
20%-30% • 25%
10%-20% • 25%
Below 10% • 25%
More than 20% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
Exit market • 25%
No significant change • 25%
Decrease • 25%
Increase • 25%